RadNet (NASDAQ:RDNT) Might Be Having Difficulty Using Its Capital Effectively

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd want to identify a growing return on capital employed (ROCE) and then alongside that, an ever-increasing base of capital employed. Put simply, these types of businesses are compounding machines, meaning they are continually reinvesting their earnings at ever-higher rates of return. However, after briefly looking over the numbers, we don't think RadNet (NASDAQ:RDNT) has the makings of a multi-bagger going forward, but let's have a look at why that may be.

Advertisement

Return On Capital Employed (ROCE): What Is It?

For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. The formula for this calculation on RadNet is:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

0.028 = US$64m ÷ (US$2.7b - US$434m) (Based on the trailing twelve months to June 2023).

So, RadNet has an ROCE of 2.8%. Ultimately, that's a low return and it under-performs the Healthcare industry average of 9.5%.

View our latest analysis for RadNet

roce
NasdaqGM:RDNT Return on Capital Employed August 27th 2023

In the above chart we have measured RadNet's prior ROCE against its prior performance, but the future is arguably more important. If you'd like to see what analysts are forecasting going forward, you should check out our free report for RadNet.

What Can We Tell From RadNet's ROCE Trend?

When we looked at the ROCE trend at RadNet, we didn't gain much confidence. To be more specific, ROCE has fallen from 6.3% over the last five years. Although, given both revenue and the amount of assets employed in the business have increased, it could suggest the company is investing in growth, and the extra capital has led to a short-term reduction in ROCE. If these investments prove successful, this can bode very well for long term stock performance.

What We Can Learn From RadNet's ROCE

While returns have fallen for RadNet in recent times, we're encouraged to see that sales are growing and that the business is reinvesting in its operations. And the stock has done incredibly well with a 132% return over the last five years, so long term investors are no doubt ecstatic with that result. So should these growth trends continue, we'd be optimistic on the stock going forward.

RadNet does come with some risks though, we found 3 warning signs in our investment analysis, and 1 of those is a bit concerning...

For those who like to invest in solid companies, check out this free list of companies with solid balance sheets and high returns on equity.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NasdaqGM:RDNT

RadNet

Provides outpatient diagnostic imaging services in the United States and internationally.

Reasonable growth potential with adequate balance sheet.

Advertisement

Weekly Picks

LO
Lou_Basenese
GANX logo
Lou_Basenese on Gain Therapeutics ·

The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake

Fair Value:US$7.675.4% undervalued
11 users have followed this narrative
0 users have commented on this narrative
12 users have liked this narrative
KI
NVDA logo
Kingman1152 on NVIDIA ·

NVIDIA will see a profit margin surge of 55% in the next 5 years

Fair Value:US$305.2538.0% undervalued
14 users have followed this narrative
0 users have commented on this narrative
4 users have liked this narrative
TE
BUSER logo
TechMegaTrends on Bambuser ·

Bambuser is today the only listed company in Europe that simultaneously possesses an 85% gross margin, proprietary AI infrastructure for the

Fair Value:SEK 238.2690.3% undervalued
5 users have followed this narrative
0 users have commented on this narrative
7 users have liked this narrative
HE
HedgeY
CSTM logo
HedgeY on Constellium ·

Constellium jet another cyclical aluminum processor, or a mispriced aluminum platform?

Fair Value:US$3410.6% undervalued
3 users have followed this narrative
0 users have commented on this narrative
1 users have liked this narrative

Updated Narratives

AS
AstrisCorporateAdvisory
9628 logo
AstrisCorporateAdvisory on SAN Holdings ·

Forging ahead with an ambitious growth plan

Fair Value:JP¥1.92k28.6% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
FA
VERDANT logo
FA_Trader on Verdant Solar Holdings Berhad ·

Verdant Solar: Continued share accumulation may be hinting that the worst is temporary, not structural

Fair Value:RM 0.4555.6% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DI
DinTang
P8Z logo
DinTang on Bumitama Agri ·

Expectations focused on stable output, disciplined costs, and continued cash returns to shareholders

Fair Value:S$2.4622.8% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

TR
tripledub
MSFT logo
tripledub on Microsoft ·

Everyone's Terrified Microsoft Will Keep Spending. I'm Terrified They'll Stop.

Fair Value:US$3952.7% undervalued
45 users have followed this narrative
3 users have commented on this narrative
42 users have liked this narrative
RO
Robbo
TSLA logo
Robbo on Tesla ·

The academically fascinating Tesla

Fair Value:US$301.1k% overvalued
38 users have followed this narrative
11 users have commented on this narrative
32 users have liked this narrative
AN
AnalystConsensusTarget
MSFT logo
AnalystConsensusTarget on Microsoft ·

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks

Fair Value:US$587.3134.6% undervalued
1356 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative